Medable and Masimo partner to bring wearables to clinical trials
The partnership between the two California companies enables Masimo’s pulse oximeter tech to be used in oncology trials across 25 different territories.
Clinical trial technology provider, Medable, has partnered with wearable device firm Masimo to integrate its pulse oximeter technology into clinical trials. The partnership between the California-based companies means that Masimo’s MightySat Rx pulse oximeter wearable device can now be used in clinical trials by any sponsor, with the device now available for approximately 3000 patients in 25 countries across two oncology indications: lung and breast cancer.
